Literature DB >> 15898970

Gabapentin withdrawal syndrome in the presence of a taper.

Kien T Tran1, Diane Hranicky, Tracey Lark, Nj Jacob.   

Abstract

OBJECTIVE: To report a case report of a geriatric patient with a 5-year history of gabapentin use for enhanced bipolar control, who was tapered off of gabapentin over 1 week. The patient displayed unique withdrawal symptoms after the taper of gabapentin.
METHODS: The patient is an 81-year-old white female with a life-long history of schizoaffective disorder with bipolar type I tendencies who had been prescribed gabapentin for 5 years.
RESULTS: The patient displayed moderate upper respiratory tract infection symptoms and somatic complaints 1 day after termination of gabapentin. These symptoms gradually worsened until 10 days after, at which time she acutely developed severe mental status changes, severe somatic chest pain, and hypertension. Physical examination, electrolytes, electrocardiogram, computerized tomography, magnetic resonance imaging, and magnetic resonance angiography were all normal. Upon reintroduction of gabapentin, the patient returned to baseline within 1-2 days.
CONCLUSIONS: Gabapentin is widely utilized currently for the chronic treatment of recalcitrant migraines, bipolar illness, pain, and epilepsy. It has a wide therapeutic index with few side effects and drug interactions, is not hepatically metabolized, and is excreted by the kidneys. Past reports have suggested that some withdrawal symptoms can present after 1-2 days upon abrupt discontinuation of gabapentin after chronic use within young to middle-aged patients. These symptoms mimic that of alcohol and benzodiazepine withdrawal purportedly due to a similar mechanism of action. Unique to this case is that this geriatric patient developed debilitating withdrawal symptoms after a gradual, week-long taper of gabapentin along with flu-like symptoms. It is proposed herein that a gabapentin taper should follow a course similar to that of a benzodiazepine taper -- slowly and over a period of weeks to months.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15898970     DOI: 10.1111/j.1399-5618.2005.00200.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  8 in total

Review 1.  Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Authors:  Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

Review 2.  Drug deprescription-withdrawal risk, prevention, and treatment.

Authors:  Madison K Bangert; Gabriel M Aisenberg
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-12-20

3.  Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.

Authors:  Nichole C Sanders; Michael J Mancino; W Brooks Gentry; J Benjamin Guise; Warren K Bickel; Jeff Thostenson; Alison H Oliveto
Journal:  Exp Clin Psychopharmacol       Date:  2013-07-15       Impact factor: 3.157

4.  Complex encephalopathy arising from the combination of opioids and gabapentin.

Authors:  Harpreet Singh; Richa Handa; Vivek Kak; Alicja Wasilewski
Journal:  BMJ Case Rep       Date:  2019-04-20

5.  A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia.

Authors:  Kirk J Brower; Hyungjin Myra Kim; Stephen Strobbe; Maher A Karam-Hage; Flavia Consens; Robert A Zucker
Journal:  Alcohol Clin Exp Res       Date:  2008-06-06       Impact factor: 3.455

Review 6.  Gabapentin misuse, abuse and diversion: a systematic review.

Authors:  Rachel V Smith; Jennifer R Havens; Sharon L Walsh
Journal:  Addiction       Date:  2016-03-18       Impact factor: 6.526

7.  A comprehensive review of the literature on epilepsy in selected countries in emerging markets.

Authors:  Mallik Angalakuditi; Nupur Angalakuditi
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-29       Impact factor: 2.570

Review 8.  Gabapentin in acute postoperative pain management.

Authors:  Connie Y Chang; Chaitanya K Challa; Janki Shah; Jean Daniel Eloy
Journal:  Biomed Res Int       Date:  2014-04-14       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.